Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib + gefitinib versus platinum-pemetrexed in MET-positive, EGFR-mutant NSCLC after acquired resistance to EGFR-TKI
NL-OMON46330Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tepotinib, gefitinib, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Planned start Dec 2016; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46330.